H.C. Wainwright reiterates Buy on BridgeBio stock, cites trial data
H.C. Wainwright reiterated a Buy rating and $120 price target for BridgeBio Pharma (BBIO) after positive Phase 3 trial data for encaleret. The stock trades near its fair value estimate, with a Strong Buy consensus and targets ranging from $80 to $156. BridgeBio also announced FDA acceptance of a New Drug Application for infigratinib, with a target action date in February 2027.
How this was made
The 30-second read
Why it matters
Analyst consensus remains bullish with price targets up to $156, indicating strong market confidence.
Market read
Positive Phase 3 data is a catalyst that can drive BBIO's stock higher in the near term.
What to watch
Potential competition in hypocalcemia treatments could temper upside.
Background
BridgeBio has multiple pipelines; recent FDA acceptance for infigratinib and other trial updates were also noted.
Ticker impact
BridgeBio Pharma presented positive Phase 3 CALIBRATE trial data for encaleret, showing 91% response versus 0% control.
likely upward pressure as market prices in the encouraging data
Trial data is a primary disclosure for a biotech and typically moves the stock on the day of release.
Market effects
strengthens outlook for bone‑health biotech segment
U.S. biotech sector may see modest gains
limited to investors tracking rare‑disease pipelines
Counterpoint
Some investors may wait for FDA filing before committing, citing execution risk.
Key entities
- companyBridgeBio Pharma
Biotech company developing encaleret and other rare‑disease therapies.
- analystH.C. Wainwright
Reiterated Buy rating and $120 price target on BBIO.
